With Democrats in Washington debating the specifics of the president’s infrastructure program, the pharmaceutical industry may be able to squeak out a much-desired drug pricing win.
As the negotiations unfold, Politico reports that the party leadership may have to abandon its proposal to have Medicare negotiate drug prices. Federal drug pricing negotiations are a top priority for some Democrats, but the pharmaceutical industry has staunchly opposed the idea, including through an open letter to Congress and a briefing with reporters.
